Suchergebnisse - (Subject:"Siltuximab")

PubPharm (11)

1

Advances in clinical outcomes : What we have learned during the COVID-19 pandemic

enthalten in: The Journal of allergy and clinical immunology | 2022

von Al-Musa, A. | LaBere, B. | Habiballah, S. | +2

2

Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease

enthalten in: Expert opinion on investigational drugs | 2020

von Zhou, Z. | Price, C.

3

Involvement of interleukin 6 in SARS-CoV-2 infection : siltuximab as a therapeutic option against COVID-19

enthalten in: European journal of hospital pharmacy : science and practice | 2020

von Palanques-Pastor, T. | López-Briz, E. | Poveda Andrés, J.

4

Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition

enthalten in: Infectious disease clinics of North America | 2020

von Liu, A.

5

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

enthalten in: Hematology. American Society of Hematology. Education Program | 2018

von Fajgenbaum, D.

6

The Role of Interleukin-6 in Castleman Disease

enthalten in: Hematology/oncology clinics of North America | 2018

von Yoshizaki, K. | Murayama, S. | Ito, H. | +1

7

Treatment of Idiopathic Castleman Disease

enthalten in: Hematology/oncology clinics of North America | 2018

von van Rhee, F. | Greenway, A. | Stone, K.

8

Clinical development of siltuximab

enthalten in: Current oncology reports | 2015

von Davis, C. | Shah, K. | Lechowicz, M.

9

Interleukin-6 as a therapeutic target

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2015

von Rossi, J. | Lu, Z. | Jourdan, M. | +1

10

Siltuximab : a new option for the management of Castleman's disease

enthalten in: Drugs of today (Barcelona, Spain : 1998) | 2015

von Barquero, N.